Last reviewed · How we verify
WJB001
At a glance
| Generic name | WJB001 |
|---|---|
| Sponsor | Wigen Biomedicine Technology (Shanghai) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (PHASE1, PHASE2)
- A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WJB001 CI brief — competitive landscape report
- WJB001 updates RSS · CI watch RSS
- Wigen Biomedicine Technology (Shanghai) Co., Ltd. portfolio CI